SecBot SecBot
PRESS-RELEASE ·Filed Apr 28, 2026

MESO

Mesoblast Limited
BULLISH
Impact 7/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The completion of patient recruitment removes a key binary risk and de-risks the timeline to a potential blockbuster product. Traders should watch for top-line data in mid-2027 and any partnership or licensing announcements before then. The strong insider buying and RMAT designation support a positive outlook, but the long wait for data means near-term volatility may be limited.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$15.55
T+0 close · Apr 28, 2026 · via day close
Latest settled
−1.54%
T+60 · $15.31
Vs SPY
−5.65%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 29 $15.55entry
  2. T+1 · 7mo ago +0.77%α −0.25% · $15.67
  3. T+5 · 7mo ago +1.67%α −1.44% · $15.81
  4. T+20 · 6mo ago −5.08%α −11.13% · $14.76
  5. T+60 · 4mo ago −1.54%α −5.65% · $15.31

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Mesoblast announced that its Phase 3 trial (MSB-DR004) of rexlemestrocel-L for chronic low back pain due to degenerative disc disease has completed patient recruitment. Top-line results are expected in mid-2027, with a potential FDA filing in Q3 2027. The trial targets a large U.S. market of over 7 million patients, and the drug has RMAT designation, enabling priority review.

Key Facts

  • Phase 3 trial (MSB-DR004) of rexlemestrocel-L for chronic low back pain has completed patient recruitment.
  • Top-line results expected mid-CY2027; regulatory filing with FDA planned for Q3 CY2027.
  • Rexlemestrocel-L has RMAT designation from FDA, providing priority review eligibility.
  • Target indication: chronic low back pain due to degenerative disc disease, affecting over 7 million people in the U.S.
  • Management estimates potential peak revenue >$10 billion with single-digit market penetration.
  • Earlier Phase 3 trial (MSB-DR003) showed clinically meaningful pain reduction and opioid cessation for up to three years.
  • Insider buying of $20.8M over the past 30 days (6 buys) aligns with positive sentiment.

Financial Impact

Potential peak revenue >$10 billion with single-digit market penetration; no current revenue from this product.

revenuemarket cap

Risk Factors

  • Phase 3 trial may fail to meet primary endpoint, leading to stock decline.
  • Regulatory filing and approval are not guaranteed; FDA could request additional data.
  • Long timeline to results (mid-2027) means no near-term revenue catalyst.
  • Competition from other cell therapies or non-opioid pain treatments could limit market share.

Market Snapshot

Exchange
OTC
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3283366

Track record

25 reports on MESO

Performance horizon

6 of 14 bullish or bearish reports moved the stock their way by T+1. Best: +24.95% at T+20 after the Jul 30, 2026 report. 9 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Neutral 2/10 Entry $13.25 Now $12.45 −6.04% settles Nov 17
  2. Nov 10, 20266d ago 6-K Neutral 3/10 Entry $13.65 to $13.10 Now $12.45 −8.79% ▼ −4.03% −3.68% vs SPY
  3. Nov 2, 202614d ago 6-K Neutral 2/10 Entry $14.77 to $14.29 Now $12.45 −15.71% ▼ −3.25% −4.90% vs SPY
  4. Oct 29, 202618d ago 6-K Bullish 6/10 No price data
  5. Oct 28, 202619d ago Press Release Bullish 6/10 Entry $15.67 to $15.16 Now $12.45 −20.55% ▼ −3.25% −1.48% vs SPY
  6. Oct 15, 20264w ago 6-K Bullish 6/10 Entry $13.28 to $11.95 Now $12.45 −6.25% ▼ −10.02% −10.44% vs SPY
  7. Oct 15, 20264w ago 6-K Neutral 2/10 Entry $13.95 to $13.28 Now $12.45 −10.75% ▼ −4.80% −3.70% vs SPY
  8. Oct 13, 20264w ago 6-K Mixed 6/10 Entry $13.90 to $13.79 Now $12.45 −10.40% ▼ −0.76% +0.33% vs SPY
  9. Sep 23, 20267w ago 6-K Neutral 3/10 Entry $15.48 to $15.12 Now $12.45 −19.57% ▼ −2.33% −2.87% vs SPY
  10. Aug 27, 202611w ago 20-F Bullish 6/10 Entry $18.18 to $17.44 Now $12.45 −31.52% ▼ −4.07% −3.84% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 28, 2026